Back

A Computational Approach for Exploring Herbal Inhibitors of Acetylcholinesterase in Alzheimer's Disease

Sarkar, B.; Ullah, M. A.; Prottoy, N. I.

2020-01-10 pharmacology and therapeutics
10.1101/2020.01.04.20016535 medRxiv
Show abstract

Alzheimers Disease (AD) is the most common type of age related dementia in the world. Many hypotheses shed light on several reasons that lead to AD development. The cholinergic hypothesis describes that the destruction of an essential neurotransmitter, acetylcholine (AChE) by acetylcholinesterase (AChE) enzyme, leads to the AD onset. The hydrolysis of acetylcholine by excess amount of AChE decreases the amount of acetylcholine in the brain, thus interfering with the normal brain functions. Many anti-AChE agents can be used to treat AD by targeting AChE. In our study, 14 anti-AChE agents from plants: 1,8-cineol, berberine, carvacrol, cheilanthifoline, coptisine, estragole, harmaline, harmine, liriodenine, myrtenal, naringenin, protopine, scoulerine, stylopine were tested against AChE and compared with two controls: donepezil and galantamine, using different techniques of molecular docking. Molecular docking study was conducted for all the 14 selected ligands against AChE to identify the best three ligands among them. To determine the safety and efficacy of the three best ligands, a set of tests like the druglikeness property test, ADME/T test, PASS & P450 site of metabolism prediction, pharmacophore mapping and modelling and DFT calculations were performed. In our experiment, berberine, coptisine and naringenin were determined as the three ligands from the docking study. Further analysis of these 3 ligands showed coptisine as the most potent anti-AChE agent. The molecular dynamics simulation study showed quite good stability of the coptisine-AChE docked complex. Administration of berberine, coptisine and naringenin might be potential treatments for AD.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Heliyon
146 papers in training set
Top 0.1%
14.8%
2
PLOS ONE
4510 papers in training set
Top 21%
8.6%
3
Scientific Reports
3102 papers in training set
Top 16%
6.6%
4
Frontiers in Pharmacology
100 papers in training set
Top 0.6%
4.5%
5
Alzheimer's & Dementia: Translational Research & Clinical Interventions
16 papers in training set
Top 0.1%
4.4%
6
F1000Research
79 papers in training set
Top 0.5%
3.7%
7
PeerJ
261 papers in training set
Top 2%
3.7%
8
International Journal of Molecular Sciences
453 papers in training set
Top 3%
3.2%
9
Frontiers in Medicine
113 papers in training set
Top 2%
2.7%
50% of probability mass above
10
Journal of Biomolecular Structure and Dynamics
43 papers in training set
Top 0.5%
2.4%
11
Journal of Alzheimer’s Disease
39 papers in training set
Top 0.4%
2.1%
12
Journal of Global Antimicrobial Resistance
15 papers in training set
Top 0.3%
2.1%
13
JMIRx Med
31 papers in training set
Top 0.5%
1.9%
14
Life Sciences
25 papers in training set
Top 0.5%
1.7%
15
Cureus
67 papers in training set
Top 3%
1.7%
16
Biochimie
23 papers in training set
Top 0.1%
1.5%
17
Aging
69 papers in training set
Top 2%
1.5%
18
PLOS Neglected Tropical Diseases
378 papers in training set
Top 4%
1.4%
19
ACS Omega
90 papers in training set
Top 2%
1.3%
20
Royal Society Open Science
193 papers in training set
Top 3%
1.3%
21
International Journal of Environmental Research and Public Health
124 papers in training set
Top 5%
1.1%
22
International Journal of Biological Macromolecules
65 papers in training set
Top 2%
1.1%
23
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.6%
1.0%
24
International Immunopharmacology
15 papers in training set
Top 0.3%
1.0%
25
Molecules
37 papers in training set
Top 1%
0.9%
26
Atherosclerosis
29 papers in training set
Top 1%
0.8%
27
Clinical and Translational Science
21 papers in training set
Top 1.0%
0.8%
28
RSC Advances
18 papers in training set
Top 1%
0.8%
29
The FASEB Journal
175 papers in training set
Top 3%
0.8%
30
Computational and Structural Biotechnology Journal
216 papers in training set
Top 9%
0.8%